AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Ltd. is making significant strides in the biopharmaceutical industry with a focus on cellular immunotherapy through their AdCella division and advancing partnerships in out-licensing and co-development to enhance the value of their leading drug candidate, AD-214. The company is also investing in its i-body® platform, with active discovery programs in i-CAR-T and i-PET imaging, signaling robust growth opportunities. A Memorandum of Understanding with SYNBV promises to expedite development in a cost-effective manner.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
